BR112022003735A2 - Anticorpo de domínio único para alvejar antígeno de membrana específico da próstata (psma) - Google Patents

Anticorpo de domínio único para alvejar antígeno de membrana específico da próstata (psma)

Info

Publication number
BR112022003735A2
BR112022003735A2 BR112022003735A BR112022003735A BR112022003735A2 BR 112022003735 A2 BR112022003735 A2 BR 112022003735A2 BR 112022003735 A BR112022003735 A BR 112022003735A BR 112022003735 A BR112022003735 A BR 112022003735A BR 112022003735 A2 BR112022003735 A2 BR 112022003735A2
Authority
BR
Brazil
Prior art keywords
psma
specific membrane
membrane antigen
single domain
domain antibody
Prior art date
Application number
BR112022003735A
Other languages
English (en)
Inventor
Papo Niv
Rosenfeld Lior
Original Assignee
Nat Institute For Biotechnology In The Negev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Institute For Biotechnology In The Negev Ltd filed Critical Nat Institute For Biotechnology In The Negev Ltd
Publication of BR112022003735A2 publication Critical patent/BR112022003735A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

anticorpo de domínio único para direcionar o antígeno de membrana específico da próstata (psma). a presente invenção em algumas modalidades da mesma é direcionada a um polipeptídeo de ligação ao antígeno com afinidade de ligação aumentada ao antígeno de membrana específico da próstata (psma). em algumas modalidades, a presente invenção é ainda direcionada ao uso do polipeptídeo de ligação ao antígeno no diagnóstico e tratamento de doenças associadas à expressão elevada de psma, como câncer de próstata.
BR112022003735A 2019-08-29 2020-08-30 Anticorpo de domínio único para alvejar antígeno de membrana específico da próstata (psma) BR112022003735A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962893264P 2019-08-29 2019-08-29
PCT/IL2020/050940 WO2021038571A1 (en) 2019-08-29 2020-08-30 A single-domain antibody for targeting prostate specific membrane antigen (psma)

Publications (1)

Publication Number Publication Date
BR112022003735A2 true BR112022003735A2 (pt) 2022-06-21

Family

ID=74684983

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022003735A BR112022003735A2 (pt) 2019-08-29 2020-08-30 Anticorpo de domínio único para alvejar antígeno de membrana específico da próstata (psma)

Country Status (11)

Country Link
US (1) US20220306764A1 (pt)
EP (1) EP4021941A4 (pt)
JP (1) JP2022546422A (pt)
KR (1) KR20220106956A (pt)
CN (1) CN114787192A (pt)
AU (1) AU2020335394A1 (pt)
BR (1) BR112022003735A2 (pt)
CA (1) CA3149754A1 (pt)
IL (1) IL290963A (pt)
MX (1) MX2022002371A (pt)
WO (1) WO2021038571A1 (pt)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3368559A4 (en) * 2015-10-30 2020-01-15 Aleta Biotherapeutics Inc. COMPOSITIONS AND METHODS FOR TREATING CANCER
CN105524170A (zh) * 2016-02-03 2016-04-27 南昌大学 能特异结合前列腺特异性膜抗原的纳米抗体
RU2021137547A (ru) * 2016-08-24 2022-01-11 Тенеобио, Инк. Трансгенные животные, отличные от человека, продуцирующие модифицированные антитела, содержащие только тяжелые цепи

Also Published As

Publication number Publication date
IL290963A (en) 2022-04-01
EP4021941A1 (en) 2022-07-06
KR20220106956A (ko) 2022-08-01
US20220306764A1 (en) 2022-09-29
AU2020335394A1 (en) 2022-03-24
WO2021038571A8 (en) 2022-11-17
EP4021941A4 (en) 2023-08-30
CN114787192A (zh) 2022-07-22
MX2022002371A (es) 2022-06-08
CA3149754A1 (en) 2021-03-04
WO2021038571A1 (en) 2021-03-04
JP2022546422A (ja) 2022-11-04

Similar Documents

Publication Publication Date Title
ECSP19072235A (es) Anticuerpos anti-ILT4 y fragmentos de unión a antígeno
BR112018007046A2 (pt) anticorpo isolado ou fragmento de ligação a antígeno, composição farmacêutica, molécula de polinucleotídeo isolado, vetor, célula, e, métodos para inibir o crescimento de um tumor ou de uma célula tumoral e para tratar uma doença ou distúrbio.
BR112019002035A2 (pt) tratamento de câncer usando um receptor de antígeno quimérico em combinação com um inibidor de uma molécula pró-macrófago m2
BR112017028353A2 (pt) anticorpos para cd40 com atividade agonista melhorada
ECSP12012194A (es) Proteínas ligando dll4 terapéuticas
BR112017002342A2 (pt) novos anticorpos e usos dos mesmos
BR112018002130A2 (pt) anticorpo de domínio único e proteínas derivadas respectivas contra um ligante de morte programada (pdl1)
EA201890368A1 (ru) Антитела против псма, биспецифичные антигенсвязывающие молекулы, которые связывают псма и cd3, и их применение
BR112017002080A2 (pt) ?anticorpo monoclonal ou fragmento de ligação, molécula de ácido nucleico isolada, vetor, célula hospedeira, métodos para preparar o anticorpo monoclonal ou fragmento de ligação, in vivo ou in vitro e para prevenção e/ou tratamento e/ou terapia adjuvante e/ou diagnóstico de um tumor, conjugado, kit, uso de um anticorpo monoclonal ou fragmento de ligação, e, composição farmacêutica?
BR112017027549A2 (pt) anticorpo para cd40
UY37591A (es) Conjugados de fármaco anticuerpo
BR112018070948A2 (pt) anticorpos anti-psma e utilização dos mesmos
UY30525A1 (es) Agentes de union dirigidos cuyo blanco es el pdgfr-alfa y sus usos
BR112015000776A2 (pt) Agentes de ligação à rspo3 e usos dos mesmos
PA8804901A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo
BR112016018205A8 (pt) métodos de tratamento de mal de alzheimer, de seleção de pacientes, de identificação de pacientes, de previsão, de otimização da eficácia terapêutica, kit, uso de agente e uso in vitro de agente
BR112021009275A2 (pt) Anticorpo humanizado anti-sirp alfa ou um fragmento de ligação a antígeno do mesmo, composição farmacêutica, molécula de ácido nucleico, e, célula hospedeira.
AR104484A1 (es) Anticuerpos anti-psma como agentes terapéuticos
CY1123926T1 (el) Αντισωματα κατα της τρανσγλουταμινασης 2
BR112019023909A8 (pt) Uso de um imunoconjugado que se liga a folr1, e, uso de um imunoconjugado que se liga a folr1 e pembrolizumab
CL2021001593A1 (es) Tubulisinas y conjugados de proteína-tubulisina
BR112022002012A2 (pt) Moléculas multispecíficas de ligação a antígeno para células-alvo e usos das mesma
BR112019020414A2 (pt) composições e métodos para detectar e tratar câncer de próstata usando moléculas de ligação à progastrina
BR112021017863A2 (pt) Proteína de ligação de antígeno de membrana específico de próstata, composição, método para produzir a proteína de ligação de antígeno de membrana específico de próstata
CL2021000146A1 (es) Anticuerpos humanizados contra psma

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]